37 results on '"Tebas, Pablo"'
Search Results
2. Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria
3. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons
4. A prospective 18F-fluorodeoxyglucose positron emission tomography/computed tomography study of the neurometabolic effects in cocaine use and HIV infection
5. A prospective 18F-FDG PET/CT study of the neurometabolic effects in cocaine use and HIV infection
6. The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy
7. Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation
8. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation
9. Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease
10. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
11. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults
12. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption
13. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants
14. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
15. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
16. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection
17. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142*
18. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals
19. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals
20. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men
21. Genetic analysis implicates resistin in HIV lipodystrophy
22. Massively parallel pyrosequencing in HIV research
23. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV
24. Progression of carotid artery intima–media thickening in HIV-infected and uninfected adults
25. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
26. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
27. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D
28. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
29. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression
30. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy
31. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
32. Response to ‘Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy’ by Drs Weil and Lenhard
33. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)
34. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
35. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
36. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
37. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+T cells regardless of major histocompatibility complex class 1 downregulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.